Skip to main content

Valproic Acid in Epilepsy

Pregnancy-Related Issues

Drug Safety volume 29, pages 1–21 (2006)Cite this article

Abstract

Valproic acid (sodium valproate) is widely used as a first-line antiepileptic agent. As with many antiepileptic drugs, there are a number of consequences associated with the use of valproic acid in women of child-bearing potential. Most pregnancies have a favourable outcome in women with epilepsy, and these women should not be discouraged from becoming pregnant. Unlike many other antiepileptic drugs, valproic acid has no significant pharmacokinetic interactions with the steroid hormones used in oral contraceptives. During pregnancy, the major risks to mother and child result from loss of seizure control on the one hand, and an elevated risk of major congenital malformations due to antiepileptic drug treatment on the other. In particular, an elevated risk of major congenital malformations associated with valproic acid use has been a consistent finding in studies of patient registries and several large case series. In addition, developmental delay, characterised by low verbal IQ, has also been reported in children exposed to valproic acid in utero, although the relative risk is not precisely known. For these reasons, pregnancies in women being treated with valproic acid need to be planned, and the benefit-risk ratios associated with continuing valproic acid or changing treatment need to be discussed with the patient. When treatment with valproic acid is the most appropriate treatment to achieve optimal seizure control, a number of measures can be implemented to minimise risk to the fetus. These include the use of the lowest possible effective dose of valproic acid in monotherapy (ideally <1000 mg/day), appropriate folic acid supplementation and close antenatal monitoring. Regular counselling is a prerequisite for informed planning of pregnancies and optimisation of the probability of a healthy outcome. Future research on valproic acid and pregnancy should involve risk assessment in large, population-based prospective studies.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Fig. 1
Fig. 2
Fig. 3
Table II
Table III
Fig. 4

References

  1. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester (MN). Mayo Clin Proc 1996; 71: 576–86

    PubMed  Article  CAS  Google Scholar 

  2. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003; 16: 165–70

    PubMed  Article  Google Scholar 

  3. Groupe CAROLE (Coordination Active du Reseau Observatoire Longitudinal de l’Epilepsie). Treatment of newly diagnosed epileptic crises: a French experience. Rev Neurol 2001; 157: 1500–12

    Google Scholar 

  4. Moran NF, Poole K, Bell G, et al. Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. Seizure 2004; 13: 425–33

    PubMed  Article  CAS  Google Scholar 

  5. Semah F, Picot MC, Derambure P, et al. The choice of antiepileptic drugs in newly diagnosed epilepsy: a national French survey. Epileptic Disord 2004; 6: 255–65

    PubMed  Google Scholar 

  6. Thomas P, Genton P, Gelisse P, et al. Juvenile myoclonic epilepsy. In: Roger J, Bureau M, Dravet C, eaet al., editors. Epileptic syndromes in infancy, childhood and adolescence. 3rd ed. Eastleigh: John Libbey & Co Ltd, 2002: 335–55

    Google Scholar 

  7. Janz D, Dam M, Richens A. Epilepsy, pregnancy and the child. NewYork: Raven, 1982

    Google Scholar 

  8. Morrow JI, Russell A, Gutherie E, et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2005 Sep 12 [Epub ahead of print]

    Google Scholar 

  9. Crawford P. Epilepsy and pregnancy. Seizure. 2002; 11Suppl. A: 212–9

    PubMed  Google Scholar 

  10. Barrett C, Richens A. Epilepsy and pregnancy: report of an Epilepsy Research Foundation Workshop. Epilepsy Res 2003; 52: 147–87

    PubMed  Article  Google Scholar 

  11. Patsalos PN. Pharmacokinetic and pharmacodynamic interactions: principles and interpretative pitfalls. Epileptologia 1998; 6: 9–19

    Google Scholar 

  12. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263–72

    PubMed  Article  CAS  Google Scholar 

  13. Blum D, Sidhu J, Bulsara S, et al. A bi-directional pharmacokinetic interaction study of lamotrigine and the combined oral contraceptive (COC) pill in healthy subjects. American Pain Society 2005, Abstract 901

    Google Scholar 

  14. Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 151–4

    PubMed  Article  CAS  Google Scholar 

  15. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 570–1

    PubMed  Article  CAS  Google Scholar 

  16. Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives. A national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002; 72: 114–5

    PubMed  Article  CAS  Google Scholar 

  17. Krauss GL, Brandt J, Campbell M, et al. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology 1996; 46: 1534–9

    PubMed  Article  CAS  Google Scholar 

  18. Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986; 33: 23–9

    PubMed  Article  CAS  Google Scholar 

  19. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975 Aug; 87(2): 285–90

    PubMed  Article  CAS  Google Scholar 

  20. Lindhout D, Omtzigt JG. Pregnancy and the risk of teratogenicity. Epilepsia 1992; 33Suppl. 4: S41–8

    PubMed  Article  Google Scholar 

  21. Nulman I, Scolnik D, Chitayat D, et al. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997; 68: 18–24

    PubMed  Article  CAS  Google Scholar 

  22. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33: 145–58

    PubMed  Article  CAS  Google Scholar 

  23. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132–8

    PubMed  Article  CAS  Google Scholar 

  24. Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739–46

    PubMed  Article  CAS  Google Scholar 

  25. Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 2004; 27: 197–202

    PubMed  Article  Google Scholar 

  26. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004; 45: 1171–5

    PubMed  Article  Google Scholar 

  27. Craig JJ, Morrow JI. New antiepileptic drugs: register of women who take the drugs during pregnancy has been set up [letter]. BMJ 1997; 314: 603

    PubMed  Article  CAS  Google Scholar 

  28. Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981–90

    PubMed  Article  CAS  Google Scholar 

  29. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40: 1231–6

    PubMed  Article  CAS  Google Scholar 

  30. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology. 2003; 60: 575–9

    PubMed  Article  Google Scholar 

  31. Bergmann A, Schmidt D, Hutt HG, et al. Epilepsy treatment with sustained-release formulation of valproate: experience with 1172 patients. Akt Neurol 1999; 26: 1–5

    Article  Google Scholar 

  32. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93: 174–6

    PubMed  Article  CAS  Google Scholar 

  33. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61: 673–8

    PubMed  Article  Google Scholar 

  34. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961–5

    PubMed  Article  CAS  Google Scholar 

  35. Vajda FJ, O’Brien TJ, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003; 10: 543–9

    PubMed  Article  CAS  Google Scholar 

  36. Vajda FJ, O’Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004; 11: 854–8

    PubMed  Article  CAS  Google Scholar 

  37. Cunnington M, Tennis P, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005; 64: 955–60

    PubMed  Article  CAS  Google Scholar 

  38. Russell AJ, Craig JJ, Morrison P, et al. UK epilepsy and pregnancy group [abstract]. Epilepsia 2004; 45: 1467

    PubMed  Article  Google Scholar 

  39. Craig JJ, Russell A, Parsons L, et al. The UK Epilepsy and Pregnancy Register: update of results 1996-2003 [abstract]. Epilepsia 2004; 45Suppl. 7 229

    Google Scholar 

  40. Koch S, Jager-Roman E, Losche G, et al. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr 1996; 85: 739–46

    PubMed  Article  CAS  Google Scholar 

  41. Wide K, Winbladh B, Tomson T, et al. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Dev Med Child Neurol 2000; 42: 87–92

    PubMed  Article  CAS  Google Scholar 

  42. Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37: 489–97

    PubMed  Article  CAS  Google Scholar 

  43. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 15–21

    PubMed  Article  CAS  Google Scholar 

  44. Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002; 39: 251–9

    PubMed  Article  CAS  Google Scholar 

  45. Mawer G, Clayton-Smith J, Coyle H, et al. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002; 11: 512–8

    PubMed  Article  Google Scholar 

  46. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1575–83

    PubMed  Article  CAS  Google Scholar 

  47. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62: 28–32

    PubMed  Article  CAS  Google Scholar 

  48. Holmes LB, Wyszynski DF. North American Antiepileptic Drug Pregnancy Registry [abstract]. Epilepsia 2004; 45: 1465

    PubMed  Article  Google Scholar 

  49. A North American Registry for Epilepsy and Pregnancy: a unique public/private partnership of health surveillance. Epilepsia 1998; 39: 793–8

    Google Scholar 

  50. Vajda F, Lander C, O’Brien T, et al. Australian Pregnancy Registry of Women taking antiepileptic drugs [abstract]. Epilepsia 2004; 45: 1466

    PubMed  Article  Google Scholar 

  51. Beghi E, Annegers JF; Collaborative Group for the Pregnancy Registries in Epilepsy. Pregnancy registries in epilepsy. Epilepsia 2001; 42: 1422–5

    PubMed  Article  CAS  Google Scholar 

  52. Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004; 45: 1463–4

    PubMed  Article  Google Scholar 

  53. Thomas SV, Indrani L, Devi GC, et al. Pregnancy in women with epilepsy: preliminary results of Kerala registry of epilepsy and pregnancy. Neurol India 2001; 49: 60–6

    PubMed  CAS  Google Scholar 

  54. Tennis P, Eldridge RR, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43: 1161–7

    PubMed  Article  CAS  Google Scholar 

  55. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs 1999; 57: 535–44

    PubMed  Article  CAS  Google Scholar 

  56. Jones KLJ, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320: 1661–6

    PubMed  Article  CAS  Google Scholar 

  57. Vestermark V, Vestermark S. Teratogenic effect of carbamazepine. Arch Dis Child 1991; 66: 641–2

    PubMed  Article  CAS  Google Scholar 

  58. DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473–81

    PubMed  Article  CAS  Google Scholar 

  59. Winter RM, Donnai D, Burn J, et al. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 1987; 24: 692–5

    PubMed  Article  CAS  Google Scholar 

  60. Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993; 69(3 Special No): 288–91

    PubMed  Article  CAS  Google Scholar 

  61. Christianson AL, Chesler N, Kromberg JG. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 1994; 36: 361–9

    PubMed  Article  CAS  Google Scholar 

  62. Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet 1995; 32: 724–7

    PubMed  Article  CAS  Google Scholar 

  63. Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29: 171–85

    PubMed  Article  CAS  Google Scholar 

  64. Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976; I(7954): 272–5

    Article  Google Scholar 

  65. Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976; 89: 662–8

    PubMed  Article  CAS  Google Scholar 

  66. Gaily E, Kantola-Sorsa E, Granstrom ML. Intelligence of children of epileptic mothers. J Pediatr 1988; 113: 677–84

    PubMed  Article  CAS  Google Scholar 

  67. Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990; 32: 403–14

    PubMed  Article  CAS  Google Scholar 

  68. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271: 767–70

    PubMed  Article  CAS  Google Scholar 

  69. Koch S, Titze K, Zimmermann RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40: 1237–43

    PubMed  Article  CAS  Google Scholar 

  70. Touwen BCL. Examination of the child with minor neurological dysfunction. Clin Dev Med 1979; 71: 1–72

    Google Scholar 

  71. Shorvon SD. Longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1517–8

    PubMed  Article  CAS  Google Scholar 

  72. Williams PG, Hersh JH. A male with fetal valproate syndrome and autism. Dev Med Child Neurol 1997 Sep; 39(9): 632–4

    PubMed  Article  CAS  Google Scholar 

  73. Williams G, King J, Cunningham M, et al. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001 Mar; 43(3): 202–6

    PubMed  CAS  Google Scholar 

  74. Rasalam AD, Hailey H, Williams JH, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 2005 Aug; 47(8): 551–5

    PubMed  Article  CAS  Google Scholar 

  75. Adab N, Tudur SC, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev 2004; (3): CD004848

    PubMed  Google Scholar 

  76. Tettenborn B, Genton P, Polson D. Epilepsy and women’s issues: an update. Epileptic Disord 2002; 4Suppl. 2: S23–31

    PubMed  Google Scholar 

  77. Royal College of Physicians. Adults with poorly controlled epilepsy: clinical guidelines for treatment and practical tools for aiding epilepsy management. London: Royal College of Physicians, 1997

  78. Nau H, Spielmann H. Embryotoxicity testing of valproic acid. Lancet 1983 Apr 2; 1(8327): 763–4

    PubMed  Article  CAS  Google Scholar 

  79. Barre J, Berger Y. Pharmacokinetics of a newly developed sustained-release form of sodium valproate. In: Chadwick D, editor. Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy, International Congress and Symposium Series No. 152. London: Royal Society of Medicine Services, 1989: 178–84

  80. Berto P. Quality of life in patients with epilepsy and impact of treatments. Pharmacoeconomics 2002; 20(15): 1039–59

    PubMed  Article  Google Scholar 

  81. Dean JC, Moore SJ, Osborne A, et al. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet 1999 Sep; 56(3): 216–20

    PubMed  Article  CAS  Google Scholar 

  82. Quality Standards Committee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Report of the quality standards committee of the American Academy of Neurology. Neurology 1998; 51: 944–8

  83. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131–7

    Google Scholar 

  84. Padmanabhan R, Shafiullah MM. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto) 2003; 43: 29–40

    Article  CAS  Google Scholar 

  85. Elmazar MM, Thiel R, Nau H. Effect of supplementation with folinic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in mice. Fundam Appl Toxicol 1992 Apr; 18(3): 389–94

    PubMed  Article  CAS  Google Scholar 

  86. Trotz M, Wegner C, Nau H. Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse. Life Sci 1987 Jul 6; 41(1): 103–10

    PubMed  Article  CAS  Google Scholar 

  87. Dawson JE, Raymond AM, Winn LM. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. Toxicol Appl Pharmacol 2005 Aug 19 [Epub ahead of print]

    Google Scholar 

  88. Hansen DK, Grafton TF, Dial SL, et al. Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. Teratology 1995 Nov; 52(5): 277–85

    PubMed  Article  CAS  Google Scholar 

  89. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608–14

    PubMed  Article  CAS  Google Scholar 

  90. Hendel J, Dam M, Gram L, et al. The effects of carbamazepine and valproate on folate metabolism in man. Acta Neurol Scand 1984 Apr; 69(4): 226–31

    PubMed  Article  CAS  Google Scholar 

  91. Goggin T, Gough H, Bissessar A, et al. A comparative study of the relative effects of anticonvulsant drugs and dietary folate on the red cell folate status of patients with epilepsy. Q J Med 1987 Nov; 65(247): 911–9

    PubMed  CAS  Google Scholar 

  92. Karabiber H, Sonmezgoz E, Ozerol E, et al. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev 2003 Mar; 25(2): 113–5

    PubMed  Article  Google Scholar 

  93. Bentsen KD, Gram L, Veje A. Serum thyroid hormones and blood folic acid during monotherapy with carbamazepine or valproate: a controlled study. Acta Neurol Scand 1983 Apr; 67(4): 235–41

    PubMed  Article  CAS  Google Scholar 

  94. Gidal BE, Tamura T, Hammer A, et al. Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res 2005 May; 64(3): 161–6

    PubMed  Article  CAS  Google Scholar 

  95. Kishi T, Fujita N, Eguchi T, et al. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997 Jan; 145(1): 109–12

    PubMed  Article  CAS  Google Scholar 

  96. Geda G, Caksen H, Icagasioglu D. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy. Acta Neurol Belg 2002 Sep; 102(3): 122–6

    PubMed  CAS  Google Scholar 

  97. Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8: 75–8

    PubMed  Article  CAS  Google Scholar 

  98. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992; 42Suppl. 5: 32–42

    PubMed  CAS  Google Scholar 

  99. Craig J, Morrison P, Morrow J, et al. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999; 8: 253–4

    PubMed  Article  CAS  Google Scholar 

  100. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42Suppl. 5: 149–60

    PubMed  CAS  Google Scholar 

  101. Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management of women with epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure 1999; 8: 201–17

    PubMed  Article  CAS  Google Scholar 

  102. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003; 61Suppl. 2: S23–6

    PubMed  Article  CAS  Google Scholar 

  103. Yerby MS, Kaplan P, Tran T. Risks and management of pregnancy in women with epilepsy. Cleve Clin J Med 2004; 71: S25–37

    PubMed  Article  Google Scholar 

  104. Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982; 7: 336–52

    PubMed  Article  CAS  Google Scholar 

  105. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992; 42(4 Suppl. 5): 12–6

    PubMed  CAS  Google Scholar 

  106. Malone FD, D’Altone ME. Drugs in pregnancy: anticonvulsants. Semin Perinatol1997; 21: 114–23

    PubMed  Article  CAS  Google Scholar 

  107. Kennedy D, Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psychiatry Neurosci 1998; 23: 223–8

    PubMed  CAS  Google Scholar 

  108. Shorvon S. Antiepileptic drug therapy during pregnancy: the neurologist’s perspective. J Med Genet 2002; 39: 248–50

    PubMed  Article  CAS  Google Scholar 

  109. Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 1985; 26: 631–5

    PubMed  Article  CAS  Google Scholar 

  110. Sabers A. Complications during pregnancy and delivery. In: Janz D, Dam M, Richens A, et al., editors. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 81–5

    Google Scholar 

  111. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22(1): 62–5

    PubMed  Article  CAS  Google Scholar 

  112. Anderson GD, Lin YX, Berge C, et al. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997 Aug; 87(2): 252–6

    PubMed  Article  CAS  Google Scholar 

  113. Kaaja E, Kaaja R, Matila R, et al. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 2002 Feb 26; 58(4): 549–53

    PubMed  Article  CAS  Google Scholar 

  114. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003; 61(6 Suppl. 2): S35–42

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

Funding for editorial assistance for the preparation of this article was provided by Sanofi-Aventis, the manufacturer of valproic acid.

Dr Pierre Genton has received lecturing and consultancy fees from Sanofi-Aventis, Novartis, GlaxoSmithKline, UCB and Janssen-Cilag over the past 5 years. He has also received a research grant from UCB and participated in the ‘Access to Medication’ international programme of Sanofi-Aventis in developing countries.

Dr Franck Semah has received lecturing and consultancy fees from Sanofi-Aventis, Novartis, GlaxoSmithKline, Pfizer, UCB and Janssen-Cilag over the past 5 years.

Author information

Affiliations

  1. Centre Saint-Paul, Hôpital Gastaut, 13258 Marseille 09, Marseille, France

    Pierre Genton

  2. Neurology Department, Hôpital Sainte-Anne, Paris, France

    Franck Semah

  3. Service Hospitalier Frédéric Joliot, CEA, Orsay, France

    Franck Semah

  4. Universitätsklinik für Neurologie, Medizinische Universität Innsbruck, Innsbruck, Austria

    Eugen Trinka

Authors
  1. Pierre Genton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franck Semah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eugen Trinka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Genton.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Genton, P., Semah, F. & Trinka, E. Valproic Acid in Epilepsy. Drug-Safety 29, 1–21 (2006). https://doi.org/10.2165/00002018-200629010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200629010-00001

Keywords

  • Carbamazepine
  • Valproic Acid
  • Lamotrigine
  • Congenital Malformation
  • Folic Acid Supplementation